Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab in relapsing multiple sclerosis
2024-513527-17-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Frexalimab with Placebo (2 arms). Primary endpoint: Number of new Gadolinium-enhancing T1 hyperintense lesions at week 12. Planned start Aug 2024; status: authorised.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513527-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513527-17-00.